WIXOM, Mich., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that an abstract on SFP, its lead drug candidate, has been accepted for presentation at the American Society of Nephrology (ASN) meeting to be held in San Diego CA, October 27 - November 1, 2009.
